{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:08:15Z","timestamp":1762160895918,"version":"3.38.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/shk.0b013e31822f7e58","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T18:46:41Z","timestamp":1317754001000},"page":"494-500","source":"Crossref","is-referenced-by-count":16,"title":["Valproic Acid Increases Susceptibility to Endotoxin Shock Through Enhanced Release of High-Mobility Group Box 1"],"prefix":"10.1097","volume":"36","author":[{"given":"Shinsuke","family":"Sugiura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko-ichi","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuro","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210213","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice.","volume":"285","author":"Wang","year":"1999","journal-title":"Science"},{"key":"R2-11-20210213","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/1471-2407-10-383","article-title":"Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1\/2 phosphorylation.","volume":"10","author":"Gotfryd","year":"2010","journal-title":"BMC Cancer"},{"key":"R3-11-20210213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00404-007-0423-4","article-title":"Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.","volume":"277","author":"Zhu","year":"2008","journal-title":"Arch Gynecol Obstet"},{"key":"R4-11-20210213","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R5-11-20210213","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1476-4598-9-49","article-title":"Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.","volume":"9","author":"Hrzenjak","year":"2010","journal-title":"Mol Cancer"},{"key":"R6-11-20210213","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1189\/jlb.0509363","article-title":"Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS.","volume":"87","author":"Halili","year":"2010","journal-title":"J Leukoc Biol"},{"key":"R7-11-20210213","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nbd.2009.07.019","article-title":"Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo.","volume":"36","author":"Faraco","year":"2009","journal-title":"Neurobiol Dis"},{"key":"R8-11-20210213","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12272-009-1418-4","article-title":"Anti-inflammatory effect of trichostatin-A on murine bone marrow-derived macrophages.","volume":"32","author":"Han","year":"2009","journal-title":"Arch Pharm Res"},{"key":"R9-11-20210213","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/jpet.107.120188","article-title":"Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.","volume":"321","author":"Kim","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-11-20210213","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.4049\/jimmunol.173.6.4171","article-title":"Modulation of renal disease in MRL\/lpr mice by suberoylanilide hydroxamic acid.","volume":"173","author":"Reilly","year":"2004","journal-title":"J Immunol"},{"key":"R11-11-20210213","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-11-20210213","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1084\/jem.20071728","article-title":"Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling.","volume":"205","author":"Cao","year":"2008","journal-title":"J Exp Med"},{"key":"R13-11-20210213","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"R14-11-20210213","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children.","volume":"29","author":"Herranz","year":"1988","journal-title":"Epilepsia"},{"key":"R15-11-20210213","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","article-title":"Anti-tumor mechanisms of valproate: a novel role for an old drug.","volume":"22","author":"Blaheta","year":"2002","journal-title":"Med Res Rev"},{"key":"R16-11-20210213","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0006-8993(99)02439-7","article-title":"Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB.","volume":"857","author":"Ichiyama","year":"2000","journal-title":"Brain Res"},{"key":"R17-11-20210213","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(82)91713-5","article-title":"Valproate poisoning.","volume":"2","author":"Garnier","year":"1982","journal-title":"Lancet"},{"key":"R18-11-20210213","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbalip.2011.04.014","article-title":"Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility.","volume":"1811","author":"El-Mowafy","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"R19-11-20210213","first-page":"294","article-title":"Gingival overgrowth with valproic acid: a case report.","volume":"64","author":"Anderson","year":"1997","journal-title":"ASDC J Dent Child"},{"key":"R20-11-20210213","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1128\/IAI.16.2.407-412.1977","article-title":"Biological activities of lipopolysaccharides and lipid A from Rhodospirillaceae.","volume":"16","author":"Galanos","year":"1977","journal-title":"Infect Immun"},{"key":"R21-11-20210213","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1093\/emboj\/cdg516","article-title":"Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.","volume":"22","author":"Bonaldi","year":"2003","journal-title":"EMBO J"},{"key":"R22-11-20210213","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0022-3565(25)32998-8","article-title":"Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse.","volume":"220","author":"Nau","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"R23-11-20210213","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","article-title":"Epigenetic GABAergic targets in schizophrenia and bipolar disorder.","volume":"60","author":"Guidotti","year":"2011","journal-title":"Neuropharmacology"},{"key":"R24-11-20210213","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/156802609788085250","article-title":"Histone deacetylase inhibitors in inflammatory disease.","volume":"9","author":"Halili","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"R25-11-20210213","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-05-284711","article-title":"Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.","volume":"117","author":"Roger","year":"2011","journal-title":"Blood"},{"key":"R26-11-20210213","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1007\/s00018-008-8521-4","article-title":"Valproic acid attenuates inflammation in experimental autoimmune neuritis.","volume":"65","author":"Zhang","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"R27-11-20210213","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbrc.2009.10.129","article-title":"The extracellular release of Schistosoma mansoni HMGB1 nuclear protein is mediated by acetylation.","volume":"390","author":"Carneiro","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"R28-11-20210213","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.4049\/jimmunol.177.11.7889","article-title":"Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion.","volume":"177","author":"Youn","year":"2006","journal-title":"J Immunol"},{"key":"R29-11-20210213","first-page":"119","article-title":"The mitogen-activated protein kinase pathway in rat islets of Langerhans: studies on the regulation of insulin secretion, Biochem","volume":"313","author":"Persaud","year":"1996","journal-title":"J"},{"key":"R30-11-20210213","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.carpath.2007.08.006","article-title":"C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells.","volume":"17","author":"Kawahara","year":"2008","journal-title":"Cardiovasc Pathol"},{"key":"R31-11-20210213","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/embo-reports\/kvf198","article-title":"The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.","volume":"3","author":"Gardella","year":"2002","journal-title":"EMBO Rep"},{"key":"R32-11-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"R33-11-20210213","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-065X.2007.00574.x","article-title":"High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity.","volume":"220","author":"Bianchi","year":"2007","journal-title":"Immunol Rev"},{"key":"R34-11-20210213","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1600-051X.1985.tb01377.x","article-title":"The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients.","volume":"12","author":"Seymour","year":"1985","journal-title":"J Clin Periodontol"},{"key":"R35-11-20210213","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-051x.2000.027004217.x","article-title":"Risk factors for drug-induced gingival overgrowth.","volume":"27","author":"Seymour","year":"2000","journal-title":"J Clin Periodontol"},{"key":"R36-11-20210213","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0765.2007.00996.x","article-title":"Tumor necrosis factor-alpha stimulates gingival epithelial cells to release high mobility-group box 1.","volume":"43","author":"Morimoto","year":"2008","journal-title":"J Periodontal Res"},{"key":"R37-11-20210213","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.4049\/jimmunol.0900390","article-title":"HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products.","volume":"183","author":"Qin","year":"2009","journal-title":"J Immunol"}],"container-title":["Shock"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00024382-201111000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:43:09Z","timestamp":1741783389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00024382-201111000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/shk.0b013e31822f7e58","relation":{},"ISSN":["1073-2322"],"issn-type":[{"type":"print","value":"1073-2322"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}